CNSP · Cns Pharmaceuticals Inc
United States · RS rating 62 · As of 2026-10-14
| Price | 5.35 USD |
|---|---|
| 1-day change | +0.0% |
| RS rating (overall / 1M / 3M / 12M) | 62 / 33 / 87 / 17 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 32 / 30 / 59 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +94.8% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +43.9% |
| Market cap (USD) | $2.0M |